Abstract
While chemo- and radiotherapy is far developed and successfully employed by default for cancer treatment, severe side effects point to the urgent need for more specific therapies based on the molecular mechanisms of this disease. Strategies to specifically inhibit signaling pathways that are known to force proliferation, prevent apoptosis or promote angiogenesis are expected to have a substantial impact on the future direction taken in cancer therapy. The Janus Kinase (JAK) / Signal transducer and activator of transcription (STAT) pathway is one major signaling pathway converting the signal of cytokines, growth factors and hormones into gene expression programs regulating essential cellular functions like proliferation, differentiation and survival. The suppressors of cytokine signaling (SOCS) as well as phosphatases normally tightly regulate the JAK/STAT pathway. Frequently, however this pathway is constitutively activated in a wide variety of human malignancies and substantially contributes to carcinogenesis. Consequently, new strategies for targeting the JAK/STAT pathway have been developed. This review discusses the biology of the JAK/STAT signaling pathway, which offers several molecular strategies for therapeutic interruption.
Keywords: STAT, JAK, cancer, cytokine, SOCS, signaling, inhibitors
Current Signal Transduction Therapy
Title: Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy
Volume: 1 Issue: 3
Author(s): Edith Pfitzner, Frank Nonnenmacher and Daniela Baus
Affiliation:
Keywords: STAT, JAK, cancer, cytokine, SOCS, signaling, inhibitors
Abstract: While chemo- and radiotherapy is far developed and successfully employed by default for cancer treatment, severe side effects point to the urgent need for more specific therapies based on the molecular mechanisms of this disease. Strategies to specifically inhibit signaling pathways that are known to force proliferation, prevent apoptosis or promote angiogenesis are expected to have a substantial impact on the future direction taken in cancer therapy. The Janus Kinase (JAK) / Signal transducer and activator of transcription (STAT) pathway is one major signaling pathway converting the signal of cytokines, growth factors and hormones into gene expression programs regulating essential cellular functions like proliferation, differentiation and survival. The suppressors of cytokine signaling (SOCS) as well as phosphatases normally tightly regulate the JAK/STAT pathway. Frequently, however this pathway is constitutively activated in a wide variety of human malignancies and substantially contributes to carcinogenesis. Consequently, new strategies for targeting the JAK/STAT pathway have been developed. This review discusses the biology of the JAK/STAT signaling pathway, which offers several molecular strategies for therapeutic interruption.
Export Options
About this article
Cite this article as:
Pfitzner Edith, Nonnenmacher Frank and Baus Daniela, Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy, Current Signal Transduction Therapy 2006; 1 (3) . https://dx.doi.org/10.2174/157436206778226914
DOI https://dx.doi.org/10.2174/157436206778226914 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitroimidazole Radiopharmaceuticals in Hypoxia: Part II Cytotoxicity and Radiosensitization Applications
Current Radiopharmaceuticals EBV-Related Malignancies, Outcomes and Novel Prevention Strategies
Infectious Disorders - Drug Targets Signal Transduction Therapy for Cancer - Whither Now?
Current Signal Transduction Therapy Hybrid PET/MRI for In Vivo Imaging of Cancer: Current Clinical Experiences and Recent Advances
Current Medical Imaging Molecular Imaging: Its Application In Cardiovascular Diagnosis
Current Pharmaceutical Design Chemokines as Therapeutic Targets in Non-Small Cell Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Physicochemical Properties that Determine Cellular Transport of Nanocarriers In Vitro and In Vivo
Current Organic Chemistry Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues
Current Medicinal Chemistry Oxidative Stress Upregulates PDCD4 Expression in Patients with Gastric Cancer via miR-21
Current Pharmaceutical Design Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety Azole Antimycotics - A Highway to New Drugs or a Dead End?
Current Medicinal Chemistry Honey Against Radiation-induced Oral Mucositis in Head and Neck Cancer Patients. An Umbrella Review of Systematic Reviews and Meta- Analyses of the Literature
Reviews on Recent Clinical Trials miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA Ketamine for Chronic Pain and Treatment Resistant Depression: A Mechanistic Hypothesis
Current Drug Therapy Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy
Current Pharmaceutical Design Between Bench and Bed Side: PI3K Inhibitors
Current Molecular Pharmacology Curcumin and its Multi-target Function Against Pain and Inflammation: An Update of Pre-clinical Data
Current Drug Targets Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology